Bio

Results-driven biopharmaceutical executive with extensive managerial experience in both public and private biopharmaceutical companies. Excited about the promise of Triumvira’s T cell Antigen Coupler (TAC) technology. Looking forward to bring multiple TAC targets into the clinic in years ahead! Excited to have joined the Board of ImmunoMet, a private oncology biotech, and to serve as Lead Independrnt Director for Salarius Pharmaceuticals, a public oncology company (NASDAQ: SLRX). P Previously, as President & CEO of Mirna Therapeutics, able to raise approx. $165 million in private, non-dilutive, and public funding (took company public in 2015). Served as Director on Boards of both for-profit and non-for-profit organizations. Driver of corporate goals, objectives and values, and P&L, budget and management team building responsibility in organizations of various sizes. Therapeutic experience in women’s and men’s health, neurodegenerative diseases, metabolic disorders, orphan drug diseases, and oncology.